Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm ... Read more
Novo Nordisk to establish California manufacturing site for stem cell-based ther ... Read more
Novo Nordisk A/S - Share repurchase programme ... Read more
Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm ... Read more
Novo Nordisk A/S - Share repurchase programme ... Read more
Novo Nordisk A/S - Share repurchase programme ... Read more
If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.
15 October - Novo Nordisk A/S today announced the appointment of Ludovic Helfgott as executive vice president of Biopharm, effective 3 April 2019.
Based in Zürich, Switzerland, Helfgott will lead the development of Novo Nordisk’s Biopharm business, which comprises the company’s haemophilia and human growth hormone franchises. He will be a member of Novo Nordisk’s Executive Management team and report to CEO Lars Fruergaard Jørgensen. Ludovic Helfgott joins Novo Nordisk from AstraZeneca where he most recently was global vice president in charge of the company’s Cardiovascular, Metabolism and Renal global franchise, supervising both assets in development and on the market. He joined AstraZeneca in 2005 in an international sales effectiveness role and has since held operational leadership roles with increasing responsibilities in Italy, Spain and at corporate headquarters. A French national, Helfgott holds an MBA from Insead.
Jesper Brandgaard, executive vice president, Biopharm & Legal Affairs, has decided to retire after a distinguished 20-year career at Novo Nordisk. He will remain in charge of Biopharm & Legal Affairs until Ludovic Helfgott assumes the responsibility of Novo Nordisk’s Biopharm business.
Read all the details in the announcement
2 October - In connection with the 54th EASD Annual Meeting 2018 in Berlin, Germany Novo Nordisk has today published three press releases:
1 October - Novo Nordisk today announced the establishment of a manufacturing site in Fremont, California, US to develop and produce stem cell-based therapies. The announcement follows the signing of a long-term lease on a good manufacturing practice (GMP) facility, previously operated by Asterias Biotherapeutics. The site will support Novo Nordisk’s increased commitment to develop stem-cell based therapies within type 1 diabetes and other serious chronic diseases. Once operational in 2019, the facility will fulfil the supply of stem cell-based therapies for Novo Nordisk’s clinical trial programmes.
1 October - Novo Nordisk today announced plans to make the durable, connected insulin pens NovoPen® 6 and NovoPen Echo® Plus commercially available across key markets commencing in early 2019. In parallel, to support the future integration of its connected pens with broader digital health solutions, Novo Nordisk has signed new partnership agreements with leading diabetes technology companies that share Novo Nordisk’s vision to improve the lives of people with diabetes: Dexcom, Glooko and Roche. The partnerships aim to advance the solutions available for people living with diabetes and their healthcare professionals.
24 September 2018 – Today, the Danish Government and Novo Nordisk are announcing grants of 3 and 5 million US dollars respectively to the newly established Defeat-NCD Partnership during a launch event at the UN General Assembly. These are the first grants made to the ambitious partnership that aims to initially raise 100 million dollars to fund the mobilisation of knowledge, tools, capacities and finances to scale-up action to defeat NCDs in low-resource countries.
Through four tracks of action the Partnership will contribute to:
Read more details in the press release
20 September - Novo Nordisk today announced the headline results from PIONEER 10, a phase 3a trial with oral semaglutide vs dulaglutide, both in combination with one oral antidiabetic drug in Japanese adults with type 2 diabetes. “Many people with type 2 diabetes in Japan remain uncontrolled on oral antidiabetic treatments,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “When adding oral semaglutide to the treatment of this group of people, this study has demonstrated that oral semaglutide is both well tolerated and more efficacious compared to subcutaneous dulaglutide.”
Read all the details about the PIONEER 10 results
17 August - Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all the shares of Ziylo, UK. Ziylo has been pioneering the use of their platform technology – synthetic glucose binding molecules – for therapeutic and diagnostic applications.
“We believe the glucose binding molecules discovered by the Ziylo team together with Novo Nordisk world-class insulin capabilities have the potential to lead to the development of glucose responsive insulins which we hope can remove the risk of hypoglycaemia and ensure optimal glucose control for people with diabetes,” said Marcus Schindler, SVP, Global Drug Discovery, Novo Nordisk.
Read more about Ziylo and glucose responsive insulins in the full press release
August - Twenty years after Jacob Sten Petersen embarked upon a career in diabetes research, his own daughter Vita was diagnosed with type 1 diabetes. Here he reflects on his very personal motivation to achieve a cure for type 1 diabetes and on the progress of Novo Nordisk’s stem cell research.
Watch the video with Jacob and Vita and read the full story
Many more people are today affected by chronic non-communicable diseases (NCDs) than by communicable diseases. This is not reflected in resources for health in general and much less in humanitarian crises.
The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk have partnered to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. Focus will be on ensuring efficient supply of low-cost human insulin in vials to Red Cross globally; support for ICRC’s and DRC’s health programmes; 2-3 projects to provide care to people with hypertension and diabetes in humanitarian crises to be conducted within three years.
Read CEO Lars Fruergaard's reflections and more about the partnership
Access to reliable and affordable supplies of insulin is a challenge for many in the poorest nations in the world. Lars Rebien Sørensen has pledged to extend the current programme from 2001 and expand Novo Nordisk's commitment to supply human insulin at fixed low prices to the Least Developed Countries and low-income nations; the programme will now be extended to cover selected organisations providing relief in humanitarian situations.
Read all the details about Novo Nordisk's programme on access to insulin
The diabetes challenge - get an overview of Novo Nordisk's commitment
The Cities Changing Diabetes programme’s clear aim is to accelerate the global fight against urban diabetes. Status quo is not good enough. If we can reduce obesity by 25% globally, we can bend the diabetes curve so only 1 in 10 live with diabetes.
